MARKET

SNN

SNN

Smith & Nephew
NYSE
28.88
+0.02
+0.07%
After Hours: 29.12 +0.24 +0.83% 16:08 02/23 EST
OPEN
28.66
PREV CLOSE
28.86
HIGH
28.90
LOW
28.62
VOLUME
1.12M
TURNOVER
0
52 WEEK HIGH
33.09
52 WEEK LOW
21.53
MARKET CAP
12.63B
P/E (TTM)
57.83
1D
5D
1M
3M
1Y
5Y
Needham sees orthopedics market slowing; favors Enovis, Paragon 28
Healthcare Needham sees orthopedics market slowing; favors Enovis, Paragon 28. Needham says it expects growth in the orthopedic device market to slow to 4% to 5% for 2024 and beyond. The investment bank says it sees growth in 2023 at the highest rate in over ten years.
Seeking Alpha · 4h ago
Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?
NASDAQ · 4d ago
Weekly Report: what happened at SNN last week (0212-0216)?
Weekly Report · 6d ago
Smith+Nephew Announces Commercial Launch Of Its AETOS Shoulder System For Anatomic And Reverse Shoulder Replacement At AAOS 2024 Annual Meeting
Smith+Nephew announces full commercial availability of its AETOS Shoulder System in the US. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the U.S. In 2025. The AETos Shoulder system features ATLASPLAN 3D Planning Software and Patient Specific Instrumentation. The system has received 510(k) clearance for its use with total shoulder ar Throplasty.
Benzinga · 02/13 13:10
Smith & Nephew: Report of foreign issuer
Press release · 02/12 14:06
Weekly Report: what happened at SNN last week (0205-0209)?
Weekly Report · 02/12 09:04
Smith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual Meeting
Smith+Nephew announces the premiere of its newly acquired CARTIHEAL and AGILI-C technologies. The technologies enable biological healing for Sports Medicine. Both technologies are transforming the way healthcare professionals treat soft tissue repair and improve patient outcomes. Smith+nephew will present at AAOS Annual Meeting.
Barchart · 02/12 07:00
Weekly Report: what happened at SNN last week (0129-0202)?
Weekly Report · 02/05 09:04
More
About SNN
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

Webull offers Smith & Nephew plc (ADR) stock information, including NYSE: SNN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNN stock methods without spending real money on the virtual paper trading platform.